san francisco sep 17-18 › assets › event-guide... · san francisco sep 17-18 audience breakdown...

28EXPERT

SPEAKERS

5TOP TRENDS

IN DRUG R&DNOVEL ANTIBODY CONSTRUCTS

IMMUNOTHERAPY

CAR-TCR THERAPIES

BIOMARKERS

COMPANION DIAGNOSTICS

SAN FRANCISCO SEP 17-18

AUDIENCE BREAKDOWN

Tel: (+1) 617.500.5172 Email: [email protected] @NeoSynthEvents neo-synth

SCOPE OF THE SUMMITPrecision Medicine in Blood Cancer

Blood Cancer accounts for 10% of new cancer cases diagnosed in the US. Approximately every 3 minutes one person is diagnosed

Precision: Blood Cancer will provide a unique networking opportunity to stakeholders across the R&D value chain to discuss key issues, and pro-pose solutions to common challenges.

Blood cancer R&D represents an enormous opportunity for drug de-velopers, driven by Innovative Cancer Treatment Therapies

Discussions will revolve around all the latest trends in personalized med-icine, as pertaining to this disease area, through case studies from early discovery to clinical development.

The global market for blood cancer diagnostic and drug technologies reached $24 billion in 2015 and is expected to reach $38 billion in 2020.

• NOVEL ANTIBODY CONSTRUCTS

• CAR-TCR THERAPIES

• IMMUNOTHERAPY

• BIOMARKERS

• COMPANION DIAGNOSTICS

Do You Have the Right R&D Strategies in Place to capitalize on this growth?

HIGHLIGHTS

32%26%14%12% 9% 7%

Large Drug Developers

Small & Mid-Sized Developers

Academia & Hospitals

CROs & Platform Technology

Equipment Providers

Other

48%

23%

18%

11%

VP, Director, Head

C-Level

Scientists

Managers

COMPANY TYPE JOB TITLE

% %



HIGHLIGHTSFrom a Previous Summit in the Series

Delegates from 120+ companies gave glowing reviews!



BACKGROUND OF THE SUMMIT

BENEFITS OF ATTENDING

The Promise of Targeted TherapiesWhile clinical outcomes and survival rates for blood cancer are constantly improv-ing, there is growing demand for more effective and more targeted therapies. Meanwhile, biosimilars are threatening the dominance of existing agents.

The drug development landscape is changing rapidly. No longer is the old model of ‘one drug fits all’ acceptable in commercial and regulato-ry terms. Holistic business models are being put into place with the help of large consulting organisations to ensure information sharing and clear communication across the value chain, and a ‘patient centric’ model is sought

by industry and healthcare providers. Targeted therapies promise to deliver on the consumer end; however, there are major challenges to overcome internally, in order to satisfy that de-mand and identify an efficient route to market. Every disease area has its unique challenges, and Blood Cancer has to be approached with a laser-sharp focus.

1 6

2 7

3 8

4 9

5 10

Learn about the history of successful approaches and winning strategies

Meet prospective partners and identify in-licensing and out-licensing opportunities

Broaden your horizons and look at novel pathways and molecules currently being developed

Learn about overcoming resistance as we move to 2nd and 3rd generation targeted therapies

Meet and network with your peers at the highest level of drug development targeting Blood Cancer

See the latest efforts in developing effective biomarker strategies and har-nessing the power of cancer genomics

Experience the energy and excite-ment associated with the emergence of novel immunotherapies

Gain insights into Antibody Drug Con-jugates, CAR-TCR therapies and other much talked about classes of drugs

Identify strategies to account for drug combinations early in development

Delve into the intricacies of Companion Diagnostic co-development



CONFERENCE DAY 1 - Tuesday 17th September

Blood Cancer Immunotherapy

CAR-TCR Therapies

Registration & Networking

Invited Speakers:

Invited Speakers

Speed Networking

Networking Lunch

End of Day One

8:00

9:00

2:00

10:30

1:00

5:30

Jingyi Xiang, Director, Scientific Alliaces, Eureka Therapeutics

Barbara Sennino, Associate Director, Tumor Immunology, PACT Pharma

Thomas Tan, VP, Immunology, Elstar Therapeutics

An Song, Senior VP, Immune-Onc Therapeutics

Natalie Bezman, Director, Immuno-Oncology Discovery, Bristol-Myers Squibb

Khamir Mehta, Principal Scientist, Amgen

Cyril Konto, VP Clinical Development, Allogene

MORNING SESSION

AFTERNOON SESSION

Chris Heery, CMO, Precision BioSciences

Bob Valamehr, CDO, Fate Therapeutics

Matthew Spear, CMO, Poseida Inc.

Ute Hoch, Executive Director, Nektar Therapeutics



CONFERENCE DAY 2 - Wednesday 18th September

Biomarkers / Companion Diagnostics

Novel Approaches

Registration & Networking

Invited Speakers:

Invited Speakers:

Panel Discussion

Networking Lunch

Speed Networking

Close of Conference

8:00

9:00

2:00

12:30

1:00

10:30

5:00

Vee Munugalavadla, Director, Translational Medicine, Acerta Pharma / AstraZeneca

MORNING SESSION

AFTERNOON SESSION

Jill Hood, Sr. Director, Business Development Adaptive Biotechnologies

Mark Stern, Director, Precision Medicine and CDx, Celgene

TBA, Diagnostics Leader, Genentech

Pietro Taverna, Executive Director, Translational Medicine, Sunesis

Vicki Plaks, Principal Scientist, Translational Medicine, Kite Pharma / Gilead

Angus Sinclair, VP, Oncology, IGM

Amit Choudhury, Principal Scientist: Preclinical Pharmacology & Translational Medicine, Momenta

Mathias Oelke, SVP, Head of Pre-Clinical and Platform Development , NeximmuneKyle Lorentsen, Scientist I, Preclinical Development, Teneo Bio



VENUE

PRICES AND DISCOUNTS

TEAM DISCOUNTS

REGISTRATION CHECKLIST SECURE YOUR PLACE*

3+ Delegates: 10% Discount4+ Delegates: 15% Discount5+ Delegates: 20% Discount

When you’ve made your selections

You can register your place quickly and easily online. Visit:www.precisionbloodcancer.com Contact us:If you require any further information on the event, or would like us to as-sist you in making your booking, please contact Neo-Synth via the contact details below.

Full payment is due on registration. Cancellation and Substitution Policy: Cancellations must be received in writing. If the cancellation is received more than 14 days before the conference attendees will receive a full credit to a future conference. Cancella-tions received 14 days or less (including the fourteenth day) prior to the conference will be liable for the full fee. A substitution from the same organization can be made at any time.

Changes to Conference & Agenda: Neo-Synth reserves the right to postpone or can-cel an event, to change the location or alter the advertised speakers. Neo-Synth is not responsible for any loss or damage or costs incurred as a result of substitution, alteration, postponement or cancellation of an event for any reason and including causes beyond its control including without limitation, acts of God, natural disasters, sabotage, accident, trade or industrial disputes, terrorism or hostilities.

Data Protection: The personal information shown and/or provided by you will be held in a database. It may be used to keep you up to date with developments in your in-dustry. Sometimes your details may be obtained or made available to third parties for marketing purposes. If you do not wish your details to be used for this purpose, please send an email addressed to the data manager at [email protected]

TERMS & CONDITIONS

1. Have you checked if anyone else from your business isattending? If 3 or more of you register together,you will all benefit from reduced rates.

2. Could you register your place early to takeadvantage of early booking rates?

3. Have you carefully evaluated which package willbest help you achieve your goals?

Crowne Plaza San Francisco Airport117 Airport Blvd, Burlingame, CA94010, USA

Overnight accommodation is not included in the registration fee; however, accommodation options will be sent out with your confirmation email upon registering.

*Please note: Team discounts are only valid when three or more delegates from one company book and pay at the same time. ‘Early Bird’ discounts require payment at the time of registration (or prior to the cut-off date) to secure the applicable discount. All advertised discounts cannot be combined with any other offer.

PACKAGE PRICES

INDUSTRY DELEGATE $1899 (save $300)

$599 (save $200)

$2199

$799ACADEMIC & NON-PROFIT

Register & Pay by August 23rd Standard Rates

san francisco sep 17-18 › assets › event-guide... · san francisco sep 17-18 audience breakdown...

Documents